AKTX
NASDAQ
$10.66
Akari Therapeutics Plc (AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $26.78 (+151.22%)
Market Cap
$148M
Free Cash Flow Yield
-6.52%
Beta (5Y)
0.53
Price Chart
Valuation
Market Cap$148M
P/S478368.50
P/B1.14
Profitability
EBITDA-$18M
EPS-$0.03
Financial Health
Free Cash Flow Yield-6.52%
Growth & Risk
Beta (5Y)0.53
Sharpe Ratio0.30